EMA Authorised: Esbriet (Pirfenidone) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency authorised Esbriet (pirfenidone) for idiopathic pulmonary fibrosis under Roche Registration GmbH, with decision date 10 December 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Esbriet (pirfenidone)

Snippet

Status: Authorised. Therapeutic area: Idiopathic Pulmonary Fibrosis;Lung Diseases;Respiratory Tract Diseases. MAH: Roche Registration GmbH. Decision date: 10/12/2025